Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jan 8:2020:19-0147.
doi: 10.1530/EDM-19-0147. Online ahead of print.

Adrenocortical carcinoma masquerading as pheochromocytoma: a histopathologic dilemma

Affiliations

Adrenocortical carcinoma masquerading as pheochromocytoma: a histopathologic dilemma

Impana Shetty et al. Endocrinol Diabetes Metab Case Rep. .

Abstract

Summary: Adrenocortical carcinoma (ACC) is an aggressive cancer that originates in the cortex of the adrenal gland and generally has a poor prognosis. ACC is rare but can be more commonly seen in those with cancer predisposition syndromes (e.g. Li-Fraumeni and Lynch Syndrome). The diagnosis of ACC is sometimes uncertain and it requires the use of precise molecular pathology; the differential diagnosis includes pheochromocytoma, adrenal adenoma, renal carcinoma, or hepatocellular carcinoma. We describe a case of a 57-year-old woman with Lynch Syndrome and metastatic ACC who was initially diagnosed as having pheochromocytoma. The tumor was first identified at 51 years of age by ultrasound followed by a CT scan. She underwent a left adrenalectomy, and the histopathology identified pheochromocytoma. Two years later, she had tumor recurrence with imaging studies showing multiple lung nodules. Following a wedge resection by video-assisted thoracoscopic surgery (VATS), histopathology was read as metastatic pheochromocytoma at one institution and metastatic ACC at another institution. She later presented to the National Institutes of Health (NIH) where the diagnosis of ACC was confirmed. Following her ACC diagnosis, she was treated with mitotane and pembrolizumab which were stopped due to side effects and progression of disease. She is currently receiving etoposide, doxorubicin, and cisplatin (EDP). This case highlights the importance of using a multi-disciplinary approach in patient care. Thorough evaluation of the tumor's pathology and analysis of the patient's genetic profile are necessary to obtain the correct diagnosis for the patient and can significantly influence the course of treatment.

Learning points: Making the diagnosis of ACC can be difficult as the differential diagnosis includes pheochromocytoma, adrenal adenoma, renal carcinoma, or hepatocellular carcinoma. Patients with Lynch Syndrome should undergo surveillance for ACC as there is evidence of an association between Lynch Syndrome and ACC. Conducting a complete tumor immunoprofile and obtaining a second opinion is very important in cases of suspected ACC in order to confirm the proper diagnosis. A multi-disciplinary approach including genetic testing and a thorough evaluation of the tumor's pathology is imperative to ensuring that the patient receives an accurate diagnosis and the appropriate treatment.

Keywords: 2020; Adrenal; Adrenalectomy; Adrenocortical carcinoma; Adult; Anthracyclines; Asthenia; CT scan; Calretinin*; Cisplatin; Cyclophosphamide*; Dacarbazine; Doxorubicin; Endoscopy; Etoposide; Female; Flushing; Gallium scan; Genetics; Haematoxylin and eosin staining; Headache; Histopathology; Hypertension; Immunohistochemistry; January; KI-67*; Lynch Syndrome*; MRI; Mitotane; Oncology; PET scan; Pathology; Pembrolizumab*; Resection of tumour; SF-1*; Sandostatin*; Statins; Synaptophysin; Thorascopic surgery*; Ultrasound scan; Unique/unexpected symptoms or presentations of a disease; United States; Vimentin*; Vincristine*; White.

PubMed Disclaimer

Figures

Figure 1
Figure 1
(A) MRI of the abdomen showed a 1.4 × 0.9 cm left adrenal mass. (B) CT (computed tomography) scan of the abdomen showed a left adrenal mass that measured 2.3 × 2.9 × 1.9 cm with 91.7 Hounsfield Units on post-contrast imaging. (C) Subsequently a CT scan of the chest showed no evidence of disease (D) while a follow-up CT showed multiple lung nodules.
Figure 2
Figure 2
CT (computed tomography) of the chest, abdomen, and pelvis demonstrates tumor progression of multiple lung metastases and a metastatic splenic mass.
Figure 3
Figure 3
(A) Anterior MIP (maximal intensity projection) images with intense uptake on 18F-Fluorodeoxyglucose (18FDG) PET/CT scan (B) and negative uptake on 68Ga-dotatate PET/CT scan.
Figure 4
Figure 4
(A) Low power of the adrenocortical carcinoma involving the fibrous capsule (150× magnification, haemotoxylin and eosin staining). (B) Higher magnification of the tumor shows small cells with dark nucleus and scant cytoplasm intermixed with lipid-rich cells with prominent clear cytoplasm (200× magnification, haemotoxylin and eosin staining). (C) The tumor cells show variation in nuclear size and nuclear pleomorphism. Mitotic figures were present (250× magnification, haemotoxylin and eosin staining). (D) Metastatic tumor in the lung. The tumor showed the same characteristics of the primary adrenal lesion (150× magnification, haemotoxylin and eosin staining). (E) Immunohistochemical staining of the tumor was negative for chromogranin (150× magnification).

References

    1. Libé R. Adrenocortical carcinoma (ACC): diagnosis, prognosis, and treatment. Frontiers in Cell and Developmental Biology 2015. 45 (10.3389/fcell.2015.00045) - DOI - PMC - PubMed
    1. Plager JE. Carcinoma of the adrenal cortex: clinical description, diagnosis, and treatment. International Advances in Surgical Oncology 1984. 329–353. - PubMed
    1. Ng L, Libertino JM. Adrenocortical carcinoma: diagnosis, evaluation and treatment. Journal of Urology 2003. 5–11. (10.1097/01.ju.0000030148.59051.35) - DOI - PubMed
    1. Challis BG, Kandasamy N, Powlson AS, Koulouri O, Annamalai AK, Happerfield L, Marker AJ, Arends MJ, Nik-Zainal S, Gurnell M. Familial adrenocortical carcinoma in association with Lynch syndrome. Journal of Clinical Endocrinology and Metabolism 2016. 2269–2272. (10.1210/jc.2016-1460) - DOI - PMC - PubMed
    1. Raymond VM, Everett JN, Furtado LV, Gustafson SL, Jungbluth CR, Gruber SB, Hammer GD, Stoffel EM, Greenson JK, Giordano TJ, et al Adrenocortical carcinoma is a lynch syndrome-associated cancer. Journal of Clinical Oncology 2013. 3012–3018. (10.1200/JCO.2012.48.0988) - DOI - PMC - PubMed

LinkOut - more resources